MacuMira

04/07/2026

Your patient tells you their vision is getting worse. Their chart says 20/40 stable. They’re probably both right.

In early and intermediate dry AMD, drusen and RPE dysfunction can impair how patients see in low light, read in a restaurant, and recognise faces, before any significant change shows up on a standard acuity test.

BCVA measures foveal cone resolution under ideal conditions. Most of what your AMD patient is actually experiencing happens outside those conditions.

Contrast sensitivity helps close that gap. It captures object-background discrimination across spatial frequencies, the visual capacity that governs real-world tasks, and research shows it detects deficits earlier and tracks functional decline more closely than BCVA changes alone.

If your AMD monitoring ends at the eye chart, there’s meaningful clinical data you’re not seeing.

03/31/2026

Dry AMD has had a treatment gap for too long.

We built MacuMira to fill it. 👁️

Swipe to learn about the first Health Canada approved treatment for visual function improvement in dry AMD.

✉️ Send us a message to learn more.

02/26/2026

For patients with dry AMD, MacuMira’s first 10 days of treatment often lead to noticeable vision improvements. While results vary, this simple therapy is designed to help with everyday vision challenges and improve quality of life.

For more information, visit MacuMira.com or click the link in our bio.

https://macumira.com/

02/24/2026

As an eye care professional, you understand the challenges your patients with dry AMD face. Offering them a treatment that improves visual function can significantly increase their quality of life.

MacuMira provides a new standard of care, helping you enhance your practice by delivering a trusted, noninvasive solution.

To learn more about how MacuMira can benefit your patients and your practice, visit MacuMira.com or click the link in our bio.

https://macumira.com/

02/17/2026

Regular eye exams are essential for managing vision changes and preserving your quality of life. Small steps can go a long way in adapting to vision changes and preserving what matters most.

Let’s work together to raise awareness and support those navigating dry AMD. For more information, visit MacuMira.com or click the link in our bio.

https://macumira.com/

02/10/2026

Differentiate your practice by offering MacuMira, a first-of-its-kind therapy for dry AMD. This comfortable, in-office treatment is backed by extensive safety data and helps patients achieve meaningful improvements in their vision.

Offer your patients with dry AMD a new path forward. Learn how MacuMira can become a cornerstone of your dry AMD services by checking out the link in our bio.

https://macumira.com/

02/09/2026

02/05/2026

For those living with dry AMD, we understand how challenging and frightening it can be to face vision loss. While prevention is still key, there’s hope on the horizon. Innovative therapies like MacuMira are opening doors to better visual function and greater independence.

Let’s continue working together to bring brighter days to our patients. For more information, visit MacuMira.com or click the link in our bio.

https://macumira.com/

02/02/2026

For AMD Awareness Month, let's focus on proactive care. As eye care professionals, we know that dry AMD can gradually affect a patient's central vision, impacting daily activities like reading and recognizing faces.

By encouraging regular eye exams and discussing retinal health, we can help our patients manage their condition.

It’s also an opportunity to explore emerging therapies designed to improve visual function. Visit the link in our bio to learn how MacuMira can support your patients and your practice.

https://macumira.com/

02/01/2026

February is AMD Awareness Month.

Age-related macular degeneration affects hundreds of millions worldwide, and it’s growing fast as the population ages. The majority of cases are Dry AMD, yet for years, treatment options have been extremely limited.

Today, innovation is changing that conversation. MacuMira is designed to preserve, and in many patients, improve visual function for people living with Dry AMD, offering patients and eye care professionals a new approach grounded in clinical use.

Awareness matters. Early conversations matter. And so does expanding what’s possible for Dry AMD care.

Interested in MacuMira? Send us a message here or visit macumira.com, and let’s discuss how we can bring it to your clinic!

01/29/2026

Bringing MacuMira into your practice offers a significant opportunity: To provide your dry AMD patients with an innovative, noninvasive treatment that delivers new hope and a proven path forward.

Discover how you can become a leader in dry AMD care by visiting our website.

https://macumira.com/

01/27/2026

Bring the first clinically backed treatment for dry age-related macular degeneration into your practice with confidence and ease. Our straightforward onboarding process provides you and your team with the comprehensive tools, in-depth training, and dedicated support you need to help you deliver life-changing care.

Together, let’s set a new standard for patient outcomes and redefine what's possible for those living with dry AMD. For more information, visit MacuMira.com or click the link in our bio.

https://macumira.com/